Skip to main content
CEL SCI CORP logo

CEL SCI CORP — Investor Relations & Filings

Ticker · CVM ISIN · US1508377066 LEI · 549300FIWOFSETIVMI17 US Professional, scientific and technical activities
Filings indexed 1,081 across all filing types
Latest filing 2016-01-05 Director's Dealing
Country US United States of America
Listing US CVM

About CEL SCI CORP

https://cel-sci.com/

CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2016-01-05 English
ANNUAL REPORT
Annual Report FY 2015
2015-12-11 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-11-02 English
Regulatory Filings 2015
Regulatory Filings
2015-11-02 English
Regulatory Filings 2015
Regulatory Filings
2015-10-28 English
Regulatory Filings 2015
Regulatory Filings
2015-10-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.